Novel ctla4-ig immunoadhesins
US-2016264643-A1 · Sep 15, 2016 · US
Antibody Fc mutants with ablated effector functions
US10053513B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10053513-B2 |
| Application number | US-201514818864-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 5, 2015 |
| Priority date | Nov 30, 2009 |
| Publication date | Aug 21, 2018 |
| Grant date | Aug 21, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
First claim
Opening claim text (preview).
What is claimed: 1. An isolated Fc-containing molecule, comprising a mutated IgG1 or IgG4 Fc domain and having binding reduced by at least 800 fold or undetectable binding to a Fcγ receptor (FcγR), selected from the group consisting of FcγRI, FcγRIIa-H131 variant, FcγRlIa-R131 variant, FcγRIIb, and FcγRIII-V158 variant, as compared to an Fc-containing molecule with a wild type Fc domain, wherein the mutated IgG1 Fc comprises the mutations L234A, L235A, G237A P238S, H268A, A330S, and P331S, and wherein the mutated IgG4 Fc comprises the mutations S228P, F234A, L235A, G237A, and P238S. 2. The molecule of claim 1 comprising an antibody Fc domain with a mutated IgG1 region comprising mutations L234A, L235A, G237A, P238S, H268A, A330S and P331S. 3. The molecule of claim 1 , wherein the molecule is an antibody, an antibody fragment or an Fc region. 4. The molecule of claim 1 comprising an antibody Fc domain with a mutated IgG4 region comprising mutations S228P, F234A, L235A, G237A, and P238S. 5. A pharmaceutical composition comprising the Fc containing molecule of claim 1 and a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
comprising antibodies · CPC title
Antibody-dependent cellular cytotoxicity [ADCC] · CPC title
characterized by effect upon binding to a cell or to an antigen · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
- C07K16/32Primary
against translation products of oncogenes · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10053513B2 cover?
- Antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
- Who is the assignee on this patent?
- Janssen Biotech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/32. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).